These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 38141473)
41. An Age Adjusted Comorbidity Index to Predict Long-Term, Other Cause Mortality in Men with Prostate Cancer. Daskivich TJ; Kwan L; Dash A; Saigal C; Litwin MS J Urol; 2015 Jul; 194(1):73-8. PubMed ID: 25623745 [TBL] [Abstract][Full Text] [Related]
42. Increased risk of suicide in New South Wales men with prostate cancer: Analysis of linked population-wide data. Smith DP; Calopedos R; Bang A; Yu XQ; Egger S; Chambers S; O'Connell DL PLoS One; 2018; 13(6):e0198679. PubMed ID: 29897979 [TBL] [Abstract][Full Text] [Related]
43. Does comorbidity interact with prostate cancer to increase mortality? A Danish cohort study of 45 326 prostate cancer patients diagnosed during 1995-2011. Ording AG; Horváth-Puhó E; Lash TL; Ehrenstein V; Borre M; Vyberg M; Sørensen HT Acta Oncol; 2016 May; 55(5):611-8. PubMed ID: 26586474 [TBL] [Abstract][Full Text] [Related]
44. Comparative Performance of Diagnosis-based and Prescription-based Comorbidity Scores to Predict Health-related Quality of Life. Mehta HB; Sura SD; Sharma M; Johnson ML; Riall TS Med Care; 2016 May; 54(5):519-27. PubMed ID: 26918403 [TBL] [Abstract][Full Text] [Related]
45. Validation of the prostate cancer comorbidity index in predicting cause-specific mortality in men undergoing radical prostatectomy. Chen MS; Howard LE; Stock S; Dolgner A; Freedland SJ; Aronson W; Terris M; Klaassen Z; Kane C; Amling C; Cooperberg M; Daskivich TJ Prostate Cancer Prostatic Dis; 2023 Dec; 26(4):715-721. PubMed ID: 35668181 [TBL] [Abstract][Full Text] [Related]
46. Use of comorbidity scores for control of confounding in studies using administrative databases. Schneeweiss S; Maclure M Int J Epidemiol; 2000 Oct; 29(5):891-8. PubMed ID: 11034974 [TBL] [Abstract][Full Text] [Related]
47. Comparative performance and external validation of the multivariable PREDICT Prostate tool for non-metastatic prostate cancer: a study in 69,206 men from Prostate Cancer data Base Sweden (PCBaSe). Thurtle D; Bratt O; Stattin P; Pharoah P; Gnanapragasam V BMC Med; 2020 Jun; 18(1):139. PubMed ID: 32539712 [TBL] [Abstract][Full Text] [Related]
48. The Australian Injury Comorbidity Index to Predict Mortality. Fernando DT; Berecki-Gisolf J; Newstead S; Ansari Z Ann Emerg Med; 2020 Mar; 75(3):339-353. PubMed ID: 31955941 [TBL] [Abstract][Full Text] [Related]
49. Predictive performance of comorbidity measures in administrative databases for diabetes cohorts. Lix LM; Quail J; Fadahunsi O; Teare GF BMC Health Serv Res; 2013 Aug; 13():340. PubMed ID: 24059446 [TBL] [Abstract][Full Text] [Related]
50. Australian validation of the Cancer of the Prostate Risk Assessment Post-Surgical score to predict biochemical recurrence after radical prostatectomy. Beckmann K; O'Callaghan M; Vincent A; Roder D; Millar J; Evans S; McNeil J; Moretti K ANZ J Surg; 2018 Mar; 88(3):E183-E188. PubMed ID: 28471003 [TBL] [Abstract][Full Text] [Related]
51. Influence of comorbidity on mortality in patients with epilepsy and psychogenic nonepileptic seizures. Tan M; Pearce N; Tobias A; Cook MJ; D'Souza WJ Epilepsia; 2023 Apr; 64(4):1035-1045. PubMed ID: 36740578 [TBL] [Abstract][Full Text] [Related]
52. A retrospective analysis of Victorian and South Australian clinical registries for prostate cancer: trends in clinical presentation and management of the disease. Ruseckaite R; Beckmann K; O'Callaghan M; Roder D; Moretti K; Millar J; Evans S BMC Cancer; 2016 Aug; 16():607. PubMed ID: 27496055 [TBL] [Abstract][Full Text] [Related]
53. Comparison of three comorbidity measures for predicting health service use in patients with osteoarthritis. Dominick KL; Dudley TK; Coffman CJ; Bosworth HB Arthritis Rheum; 2005 Oct; 53(5):666-72. PubMed ID: 16208675 [TBL] [Abstract][Full Text] [Related]
54. Patterns of comorbidities in women with breast cancer: a Canadian population-based study. Ng HS; Vitry A; Koczwara B; Roder D; McBride ML Cancer Causes Control; 2019 Sep; 30(9):931-941. PubMed ID: 31280456 [TBL] [Abstract][Full Text] [Related]
55. Measurement properties of comorbidity indices in maternal health research: a systematic review. Aoyama K; D'Souza R; Inada E; Lapinsky SE; Fowler RA BMC Pregnancy Childbirth; 2017 Nov; 17(1):372. PubMed ID: 29132349 [TBL] [Abstract][Full Text] [Related]
56. Prescription rates for drugs used in treatment of benign prostatic hyperplasia and erectile dysfunction before and after prostate cancer diagnosis. Duun-Henriksen AK; Dehlendorff C; Røder MA; Skriver C; Pottegård A; Friis S; Brasso K; Larsen SB Acta Oncol; 2022 Aug; 61(8):931-938. PubMed ID: 35666094 [TBL] [Abstract][Full Text] [Related]
57. Adapting the Elixhauser comorbidity index for cancer patients. Mehta HB; Sura SD; Adhikari D; Andersen CR; Williams SB; Senagore AJ; Kuo YF; Goodwin JS Cancer; 2018 May; 124(9):2018-2025. PubMed ID: 29390174 [TBL] [Abstract][Full Text] [Related]
58. Late mortality in people with cancer: a population-based Australian study. Koczwara B; Meng R; Miller MD; Clark RA; Kaambwa B; Marin T; Damarell RA; Roder DM Med J Aust; 2021 Apr; 214(7):318-323. PubMed ID: 33296507 [TBL] [Abstract][Full Text] [Related]
59. Use of a self-report-generated Charlson Comorbidity Index for predicting mortality. Chaudhry S; Jin L; Meltzer D Med Care; 2005 Jun; 43(6):607-15. PubMed ID: 15908856 [TBL] [Abstract][Full Text] [Related]
60. Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer. Daskivich TJ; Fan KH; Koyama T; Albertsen PC; Goodman M; Hamilton AS; Hoffman RM; Stanford JL; Stroup AM; Litwin MS; Penson DF Ann Intern Med; 2013 May; 158(10):709-17. PubMed ID: 23689764 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]